Journal of Psychosocial Nursing and Mental Health Services
August 30, 2021
Karan S Kverno, Emma Mangano
121 citations
Approximately 30% of people treated for a major depressive episode will not achieve remission after two or more treatment trials of first-line antidepressants and are considered to have treatment-resistant depression (TRD). Because the odds of remission decrease with every subsequent medication trial, it is important for clinicians to understand the characteristics and risk factors for TRD,...
Cureus
August 21, 2021
Alisha Sapkota, Hajra Khurshid, Israa A Qureshi et al.
44 citations
Intranasal form of esketamine, the S-enantiomer of racemic ketamine, was approved by the US FDA in 2019 for treatment-resistant depression (TRD) in adults. Since intranasal esketamine is a newly approved drug with a novel mechanism of action, much still remains unknown in regard to its use in TRD. The objective of this study is to systematically review the latest existing evidence on intranasal...
Research, Society and Development
August 19, 2021
Frederico Marques Silveira, Amanda Pereira Mendes, Mayara Rodrigues Dos Santos et al.
1 citation
Cancer is not limited to the physical dimension, but it also affects the entire biopsychosocial context in which the patient is inserted, making him more susceptible to psychiatric disorders such as depression and anxiety. These often require pharmacological intervention, and the use of psilocybin, a substance found in mushroom species, is one of the alternatives considered today. The present...
Frontiers in Psychology
August 17, 2021
Fiamma Cavallero, Michael C. Gold, Eric Tirrell et al.
Background: Mindfulness-Based Cognitive Therapy (MBCT) has been shown to enhance the long-term treatment outcomes for major depressive disorder (MDD), and engagement of specific brain activities during brain stimulation may produce synergistic effects. Audio-guided meditation exercises are a component of MBCT that might be combined with standard transcranial magnetic stimulation (TMS) therapy...
The British Journal for the Philosophy of Science
August 16, 2021
Cecily M. K. Whiteley
19 citations
First-person reports of Major Depressive Disorder reveal that when an individual becomes depressed a profound change or ‘shift’ to one’s conscious experience occurs. The depressed person reports that something fundamental to their experience has been disturbed or shifted; a change associated with the common but elusive claim that when depressed one finds oneself in a ‘different world’ detached...
Pharmaceuticals
August 12, 2021
Gniewko Więckiewicz, Iga Stokłosa, Magdalena Piegza et al.
30 citations
Despite many different kinds of substances available for depression treatment, depression itself still appears to be a clinical challenge. Recently, formerly illicit substances came to scientists’ attention, including lysergic acid diethylamide (LSD), psilocybin and dimethyltryptamine (DMT). Some studies suggest that these substances might be effective in depression treatment. The aim of this...
Experimental and therapeutic medicine
August 5, 2021
Ioana Rădulescu, A. Drăgoi, S. Trifu et al.
In modern society, depression is one of the most common mental illness; however, its pathophysiology is not yet fully understood. A great body of evidence suggests that depression causes changes in neuroplasticity in specific regions of the brain which are correlated to symptom severity, negative emotional rumination as well as fear learning. Depression is correlated with atrophy of neurons in...
European Journal of Medical and Health Sciences
August 5, 2021
Tatiana Zydb, Michael Hart
4 citations
Background: Treatment resistant depression (TRD) is defined as a major depressive episode that does not improve in response to at least two trials, each of a different class, of antidepressant medication. Pharmacotherapy of TRD with low dose ketamines has been shown as relatively successful in recent studies. Effects of such pharmacotherapy can be augmented by combining ketamine with...
Journal of Psychosomatic Research
August 2, 2021
Tatjana Ewais, Jake Begun, Maura Kenny et al.
BACKGROUND Mindfulness-based cognitive therapy (MBCT) is a promising adjunctive treatment for adolescents and young adults (AYAs) with Inflammatory Bowel Disease (IBD) and comorbid depression. OBJECTIVES This pilot randomised controlled trial (RCT) aimed to evaluate feasibility and efficacy of an adapted MBCT program for AYA, aged 16-29, with IBD. METHODS Sixty-four AYAs were randomly allocated...
CNS Spectrums
August 1, 2021
Mu-Hong Chen, Wei-Chen Lin, Hui-Ju Wu et al.
AbstractBackgroundThe antidepressant effect of low-dose ketamine infusion on Taiwanese patients with anxious vs nonanxious treatment-resistant depression (ANX-TRD vs NANX-TRD) has remained unknown.MethodsIn total, 71 patients with TRD were randomized to three groups. Each group had participants who received saline infusions mixed with 0 (a normal saline infusion), 0.2, and 0.5 mg/kg of...
Neuropsychiatric Disease and Treatment
August 1, 2021
Alina Wilkowska, A. Włodarczyk, Maria Gałuszko‐węgielnik et al.
33 citations
Purpose Bipolar disorder is a chronic and recurrent condition often associated with treatment resistance and suicidality. There is an unmet need for effective treatment in this group of patients. Ketamine has been demonstrated to have antidepressant and antisuicidal properties in unipolar depression. Most of the available studies concern unipolar depression. Here, we present the efficacy and...
L'Encephale
August 1, 2021
Lucie Berkovitch, Bruno Romeo, Laurent Karila et al.
25 citations
Psychedelics are powerful psychoactive substances. Natural psychedelics have been used for millennia by human civilizations, in particular in Latin America, while synthetic psychedelics were discovered in the 50s, giving rise to a lot of research before they were prohibited. More recently, their therapeutic properties have been studied especially to help patients with psychiatric conditions,...
Neuropharmacology
August 1, 2021
Chrislean Jun Botanas, Raly James Perez Custodio, Hee Jin Kim et al.
13 citations
The newfound antidepressant efficacy of ketamine has provided opportunities for the development of new-generation, rapid-acting, glutamate-based antidepressants. We previously identified that methoxetamine (MXE), a ketamine analog, and an N-Methyl-d-aspartate (NMDA) receptor antagonist, produced rapid and sustained antidepressant effects in mice. MXE (R, S (±)-MXE) is a racemic mixture...
Journal of Psychopharmacology
August 1, 2021
Rachael Sumner, Emme Chacko, Rebecca McMillan et al.
68 citations
Ketamine is central to one of the most rapidly growing areas of neuroscientific research into novel treatments for depression. Limited research has indicated that the psychedelic properties of ketamine may play a role in its antidepressant effects. The aim of the current study was to explore the psychedelic experiences and sustained impact of ketamine in major depressive disorder. In the...
Anxiety, Stress, and Coping
July 31, 2021
Olga Vorontsova-Wenger, Paolo Ghisletta, Valentin Ababkov et al.
This study aimed to evaluate the effectiveness of a short mindfulness intervention on anxiety, stress and depression symptoms, as well as on inhibition of dominant responses and academic performance among university students. Fifty volunteers (M(age) = 23.8; SD = 5.3) with high levels of depression, anxiety or stress were randomly allocated to a mindfulness practice group or an active control...
Frontiers in Psychology
July 29, 2021
Roberta Antonini Philippe, Laurie Schwab, Michele Biasutti
The first wave of the COVID-19 pandemic generated a significant number of stressors that the Swiss population had to deal with. In order to cope with and adapt to such adversity, it is essential to have protective factors that allow for resilience. The objective of this study was to investigate the effects of mindfulness and physical activity on depression and resilience during the first wave...
Life
July 29, 2021
Dominika Psiuk, Emilia Nowak, Krystian Cholewa et al.
13 citations
Due to an increasing number of depression diagnoses and limited effective treatments, researchers continue to explore novel therapeutic strategies for this disorder. Recently, interest has revolved around the use of serotonergic psychedelics to reduce the symptoms of depression. In this systematic review, we summarize the currently available knowledge on the safety and efficacy of psychedelic...
July 27, 2021
A mood disorder study published in the New England Journal of Medicine is a bullet unto itself. Use of escitalopram, not a placebo, for the comparison group—another rarity! And the results? Well, not better, but equivalent. Here comes big pharmaceutical company money.
Sumerianz journal of social science
July 24, 2021
C. Griffith
Unipolar major depressive disorder affects a significant number of individuals across the globe placing at the top of the list as the leading cause of disability, related to damaging ramifications on the well-being affected persons and the societies. The current standard antidepressants targeting monoamine systems take long in starting a response. Therefore, there is a need in depression...
Medicine
July 23, 2021
A. Włodarczyk, Wiesław Jerzy Cubała, Maria Gałuszko‐węgielnik et al.
23 citations
Abstract There is evidence for ketamine use in treatment-resistant depression (TRD). Several safety and tolerability concerns arise regarding adverse drug reactions and specific subpopulations. This paper aims to investigate the relationship between dissociative and psychometric measures in course of intravenous ketamine treatment in TRD inpatients with major depressive disorder and bipolar...